| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/01/2006 | EP1628972A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
| 03/01/2006 | EP1628968A1 4-imidazolin-2-one compounds |
| 03/01/2006 | EP1628967A1 Immunosuppressant compounds and compositions |
| 03/01/2006 | EP1628964A1 2-[2-[4-[(4-chlorophenyl) phenylmethyl] -1-piperazinyl] ethoxy] acetic acid monohydrochloride as anti-allergenic compound and process for its production |
| 03/01/2006 | EP1628961A1 Phenyl quinolines and their use as estrogen receptor modulators |
| 03/01/2006 | EP1628959A2 Crystalline forms of fexofenadine hydrochloride and processes for their preparation |
| 03/01/2006 | EP1628947A2 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| 03/01/2006 | EP1628687A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 03/01/2006 | EP1628685A2 Antiviral phosphonate analogs |
| 03/01/2006 | EP1628682A2 Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 03/01/2006 | EP1628679A2 Compositions and methods for the diagnosis and treatment of tumors of glial origin |
| 03/01/2006 | EP1628673A1 Pharmaceutical compositions comprising an extract of euphorbia prostrata |
| 03/01/2006 | EP1628671A1 Rock flour, especially dolomite-based medicament, for the treatment of cancer diseases |
| 03/01/2006 | EP1628670A2 Seaweed extract composition for treatment of diabetes and diabetic complications |
| 03/01/2006 | EP1628669A1 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 03/01/2006 | EP1628668A2 1,1-disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibito rs |
| 03/01/2006 | EP1628667A1 Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
| 03/01/2006 | EP1628666A2 Compouds and uses thereof in modulating amyloid beta |
| 03/01/2006 | EP1628664A2 Polymorphic forms of naltrexone |
| 03/01/2006 | EP1628663A2 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| 03/01/2006 | EP1628662A1 Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |
| 03/01/2006 | EP1628661A2 Modulators of vr1 receptor |
| 03/01/2006 | EP1628660A2 Methods and compositions for modulating serum cortisol levels |
| 03/01/2006 | EP1628659A1 Use of poly-aminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis |
| 03/01/2006 | EP1628658A1 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof |
| 03/01/2006 | EP1628657A2 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 03/01/2006 | EP1628656A2 Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use |
| 03/01/2006 | EP1628655A2 Antiseptic compositions, methods and systems |
| 03/01/2006 | EP1628654A2 Compounds and methods for delivery of prostacyclin analogs |
| 03/01/2006 | EP1628653A2 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system |
| 03/01/2006 | EP1628652A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 03/01/2006 | EP1628651A2 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 03/01/2006 | EP1628650A1 Compositions for the treatment of reduced blood flow |
| 03/01/2006 | EP1628649A2 Neuroprotective benzoate and benzamide compounds |
| 03/01/2006 | EP1628648A1 Deramciclane-fumarate tablets |
| 03/01/2006 | EP1628647A2 Novel lipids for transfection of nucleic acids |
| 03/01/2006 | EP1628646A2 Use of ppar-gamma agonists as anti-infective agents |
| 03/01/2006 | EP1628643A2 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
| 03/01/2006 | EP1628642A1 Controlled drug release composition resistant to in vivo mechanic stress |
| 03/01/2006 | EP1628641A2 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| 03/01/2006 | EP1628639A2 Antimicrobial quaternary ammonium organosilane coatings |
| 03/01/2006 | EP1628638A2 Antibiotic composition |
| 03/01/2006 | EP1628631A2 Methods of treating hyperproliferative cell disorders |
| 03/01/2006 | EP1628630A2 Method of mitigating the adverse effects of il-2 |
| 03/01/2006 | EP1628624A2 Methods and compositions for interferon therapy |
| 03/01/2006 | EP1628623A2 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors |
| 03/01/2006 | EP1628622A2 Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements |
| 03/01/2006 | EP1628620A2 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 03/01/2006 | EP1628619A2 4-aminopyrimidine-5-one |
| 03/01/2006 | EP1628533A2 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 03/01/2006 | EP1628532A2 Methods for the protection of memory and cognition |
| 03/01/2006 | EP1628531A2 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| 03/01/2006 | EP1551417A4 Three layer tear formulation |
| 03/01/2006 | EP1528922B1 Use of treosulfan and derivatives thereof for treating multiple sclerosis |
| 03/01/2006 | EP1503753A4 A method for inhibiting platelet aggregation |
| 03/01/2006 | EP1494691A4 Treatment of diseases involving defective gap junctional communication |
| 03/01/2006 | EP1472255B1 Aza-arylpiperazines |
| 03/01/2006 | EP1462451B1 Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof |
| 03/01/2006 | EP1455774B1 Pharmaceutical composition for treating obesity |
| 03/01/2006 | EP1453523B1 Heparin-containing ophthalmic agent |
| 03/01/2006 | EP1446119B1 Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
| 03/01/2006 | EP1438023B1 Process for preparing crystalline particles of fluticasone, beclomethasone, salmeterol and salbutamol |
| 03/01/2006 | EP1430059B1 Pharmaceutically acceptable salts of 20(s)-camptothecins |
| 03/01/2006 | EP1420757B1 Cosmetic microemulsions comprising ectoine or derivatives |
| 03/01/2006 | EP1414473B1 Oral compositions for the treatment of scalp disorders |
| 03/01/2006 | EP1414426B1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 03/01/2006 | EP1409500B1 Alkylated inositolglycans and their uses |
| 03/01/2006 | EP1392292B1 Pyranoindazoles and their use for the treatment of glaucoma |
| 03/01/2006 | EP1379203B1 Condom with an erectogenic composition |
| 03/01/2006 | EP1373494B1 Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
| 03/01/2006 | EP1363910B1 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| 03/01/2006 | EP1352654B1 Famotidine injections |
| 03/01/2006 | EP1351972B1 Lipids comprising an aminoxy group |
| 03/01/2006 | EP1347971B1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 03/01/2006 | EP1345942B1 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists |
| 03/01/2006 | EP1343790B1 Cephalosporin production |
| 03/01/2006 | EP1339710B1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 03/01/2006 | EP1339399B1 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 03/01/2006 | EP1333823A4 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 03/01/2006 | EP1324774B1 Use of a ppar delta activator for treating inflammatory conditions |
| 03/01/2006 | EP1319007B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/01/2006 | EP1311672B1 tRNA-derived inhibitors of HIV reverse transcriptase |
| 03/01/2006 | EP1311507B1 Fused pyrazole derivatives being protein kinase inhibitors |
| 03/01/2006 | EP1307192B1 Candesartan for treating migraine |
| 03/01/2006 | EP1296667B1 Compounds for preventing and/or treating urticaria |
| 03/01/2006 | EP1278520B1 Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 03/01/2006 | EP1268423B1 Indole derivatives as mcp-1 receptor antagonists |
| 03/01/2006 | EP1263475B1 Synthetic oligonucleotides as inducers of erythroid differentiation |
| 03/01/2006 | EP1244433B1 Use of non-human SHIP2 knock-out mammals |
| 03/01/2006 | EP1236737B1 Process for production of methylcobalamin |
| 03/01/2006 | EP1233962B1 Novel heterocyclic compounds and their use as medicines |
| 03/01/2006 | EP1206471B1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 03/01/2006 | EP1185948B1 Method for screening and producing compound libraries |
| 03/01/2006 | EP1183033B1 Pyrrolotriazine inhibitors of kinases |
| 03/01/2006 | EP1172109B1 Compositions for preventing and treating type i allergy |
| 03/01/2006 | EP1169465B1 Two-step immunization procedure against chlamydia infection |
| 03/01/2006 | EP1141252B1 Human delta 5-desaturase gene and uses thereof |
| 03/01/2006 | EP1140109B1 Triphasic oral contraceptive |
| 03/01/2006 | EP1135394B1 Spirocyclic thienopyrans as potassium channel activators |
| 03/01/2006 | EP1133285B1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |